These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33462236)

  • 21. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.
    Zhang L; Nguyen LXT; Chen YC; Wu D; Cook GJ; Hoang DH; Brewer CJ; He X; Dong H; Li S; Li M; Zhao D; Qi J; Hua WK; Cai Q; Carnahan E; Chen W; Wu X; Swiderski P; Rockne RC; Kortylewski M; Li L; Zhang B; Marcucci G; Kuo YH
    Nat Commun; 2021 Oct; 12(1):6154. PubMed ID: 34686664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
    Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
    Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HOTAIR suppresses PTEN via DNMT3b and confers drug resistance in acute myeloid leukemia.
    Zhou W; Xu S; Chen X; Wang C
    Hematology; 2021 Dec; 26(1):170-178. PubMed ID: 33538241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
    [No Abstract]   [Full Text] [Related]  

  • 26. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia.
    Kakiuchi S; Minami Y; Miyata Y; Mizutani Y; Goto H; Kawamoto S; Yakushijin K; Kurata K; Matsuoka H; Minami H
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
    Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
    Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.
    Massé A; Roulin L; Pasanisi J; Penneroux J; Gachet S; Delord M; Ali A; Alberdi A; Berrou J; Passet M; Hernandez L; Quentin S; Gardin C; Raffoux E; Adès L; Braun T; Soulier J; Clappier E; Dombret H; Puissant A; Itzykson R
    Leuk Res; 2019 Dec; 87():106269. PubMed ID: 31751766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 32. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
    Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
    Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia.
    Rota SG; Roma A; Dude I; Ma C; Stevens R; MacEachern J; Graczyk J; Espiritu SMG; Rao PN; Minden MD; Kreinin E; Hess DA; Doxey AC; Spagnuolo PA
    Mol Cancer Ther; 2017 Nov; 16(11):2618-2626. PubMed ID: 28835383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
    Laing AA; Harrison CJ; Gibson BES; Keeshan K
    Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STC1 interference on calcitonin family of receptors signaling during osteoblastogenesis via adenylate cyclase inhibition.
    Terra SR; Cardoso JC; Félix RC; Martins LA; Souza DO; Guma FC; Canário AV; Schein V
    Mol Cell Endocrinol; 2015 Mar; 403():78-87. PubMed ID: 25591908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A.
    Grandits AM; Wieser R
    Exp Hematol; 2021 Jul; 99():1-11. PubMed ID: 34029637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.
    Ho TC; LaMere M; Stevens BM; Ashton JM; Myers JR; O'Dwyer KM; Liesveld JL; Mendler JH; Guzman M; Morrissette JD; Zhao J; Wang ES; Wetzler M; Jordan CT; Becker MW
    Blood; 2016 Sep; 128(13):1671-8. PubMed ID: 27421961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
    Bruedigam C; Bagger FO; Heidel FH; Paine Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee E; Riyat S; Moore AS; Lock RB; Bullinger L; Hill GR; Armstrong SA; Williams DA; Lane SW
    Cell Stem Cell; 2014 Dec; 15(6):775-90. PubMed ID: 25479751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.